AGC acquires commercial manufacturing facility

By The Science Advisory Board staff writers

June 2, 2020 -- Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.

The automated facility was previously owned by AstraZeneca and is well designed for high-volume commercial production, AGC noted. It contains two 20,000-liter stainless steel mammalian cell bioreactors with room for four additional bioreactors and has more than twenty acres for future expansion.

AGC Biologics
Image courtesy of AGC Biologics.

AGC plants to run full-scale operations at the new facility by April 2021. It will help the company advance a higher ratio of late-phase and commercial products and support a wider range of commercial demand, the company noted.

In addition, AGC will complete facility expansion projects in Seattle, Denmark, and Japan this year and in early 2021.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here